Gentronix Ltd.

Gentronix was founded in 1999 as a spin-out from The University of Manchester to commercialise patented new technology for the early identification of genotoxic carcinogens. This technology is now available in a kit format, known as GreenScreen HC, for the early genotoxicity screening of new drug compounds.

Developed in a simple microplate format requiring less than 1mg of compound, the assay is easily automated using standard laboratory equipment. Published results and trial data demonstrate a unique combination of exceptionally high sensitivity and specificity, making GreenScreen HC the first in vitro mammalian cell assay truly suitable for early candidate screening.

GreenScreen HC

Gentronix has launched a new, accurate and fast in vitro mammalian cell genotoxicity assay - GreenScreen HC. The TK6 host cells are p53 competent and familiar to most genetic toxicology laboratories...

(0)

BlueScreen HC - S9

BlueScreen HC uses a single cell strain, which permits 8 compounds to be tested across 8 dilutions (2-fold serial), together with untreated and positive controls, in one 96-well microplate. After arra...

(0)

Gentronix was founded in 1999 as a spin-out from The University of Manchester to commercialise patented new technology for the early identification of genotoxic carcinogens. This technology is now available in a kit format, known as GreenScreen HC, for the early genotoxicity screening of new drug compounds.

Developed in a simple microplate format requiring less than 1mg of compound, the assay is easily automated using standard laboratory equipment. Published results and trial data demonstrate a unique combination of exceptionally high sensitivity and specificity, making GreenScreen HC the first in vitro mammalian cell assay truly suitable for early candidate screening.

Contact Gentronix Ltd.

Website link